LQDA - NASDAQ
Liquidia Corporation
$55.69
+1.5%Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
At a Glance
Live SnapshotLiquidia Corporation Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Liquidia Corporation Income Statement
LQDA • NASDAQ
| Liquidia Corporation Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||
158.3M | 14M | 17.5M | 15.9M | 12.9M | 739.6K | 8.1M | 2.7M | 7.3M | 13.2M | |
GROSS PROFIT | ||||||||||
(13.2M) | (5.9M) | (2.9M) | (2.9M) | (3M) | (237.7K) | (807.2K) | (121.4K) | (319.8K) | (918.8K) | |
145.1M | 8.1M | 14.6M | 13.1M | 9.8M | 501.9K | 7.3M | 2.6M | 6.9M | 12.3M | |
OPERATING INCOME | ||||||||||
(196.5M) | (129.4M) | (88M) | (51.8M) | (43.6M) | (59.6M) | (54.1M) | (37.5M) | (35M) | (28.2M) | |
(157.2M) | (81.6M) | (44.7M) | (32.4M) | (23.1M) | (27.4M) | (13.6M) | (8.8M) | (10.2M) | (4.8M) | |
(39.3M) | (47.8M) | (43.2M) | (19.4M) | (20.5M) | (32.2M) | (40.5M) | (28.7M) | (24.8M) | (23.3M) | |
-51.4M | -121.3M | -73.4M | -38.8M | -33.8M | -59.1M | -46.8M | -34.9M | -28M | -15.9M | |
PRE-TAX INCOME | ||||||||||
(24.2M) | (12.5M) | (6.3M) | (2.3M) | (762K) | (858K) | (1.4M) | (19M) | (13M) | (85.9K) | |
-17.5M | -4.8M | -2.8M | -1.2M | -729K | -673.6K | -759.9K | -18.7M | -13M | -71K | |
-17.5M | -9.1M | -5.1M | -2.2M | -782K | -673.6K | -759.9K | -18.3M | -1.1M | -71K | |
-68.9M | -130.4M | -78.5M | -41M | -34.6M | -59.8M | -47.6M | -53.1M | -29.2M | -15.9M | |
NET INCOME | ||||||||||
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (14.9K) | |
-68.9M | -130.4M | -78.5M | -41M | -34.6M | -59.8M | -47.6M | -53.1M | -29.2M | -15.9M |
SEC Filings
LQDA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 11, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 11, 2026 | May 11, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 24, 2026 | June 16, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 05, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 05, 2026 | March 05, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 09, 2026 | January 09, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 03, 2025 | November 03, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 03, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 30, 2025 | October 27, 2025 | 2025 | |
10-Q 10-Q 2025 Q2 Q2 | August 12, 2025 | June 30, 2025 | 2025 |
Related Guides
Continue your LQDA research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.